TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02747407

Intervention type: BIOLOGICAL
Intervention: Hepatitis A Vaccine

Intervention type: BIOLOGICAL
Intervention: Hepatitis A Vaccine
Study: NCT03139032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD334
Description: APD334 active treatment for 12 weeks.
Study: NCT00635141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hypertonic saline (7 %) and isotonic saline (0.9%)
Description: Patients in study arm 1 will receive hypertonic saline (7 %) during the first phase of the study and will crossover to placebo (0.9% isotonic saline) during the second phase. Both drugs will be administered via PARI LC® Star reusable nebulizer.
Study: NCT02747407

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Intervention: Tetanus Toxoid Vaccine

Intervention type: BIOLOGICAL
Intervention: Tetanus Toxoid Vaccine

Intervention type: BIOLOGICAL
Intervention: Trivalent Influenza Vaccine

Intervention type: BIOLOGICAL
Intervention: Trivalent Influenza Vaccine
Study: NCT00782301

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: maraviroc
Description: maraviroc 150 mg. p.o. b.i.d., darunavir 600 mg. p.o. b.i.d., ritonavir 100 mg. p.o. b.i.d., raltegravir 400 mg. p.o. b.i.d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etravirine
Description: etravirine 200 mg. p.o. b.i.d., darunavir 600 mg. p.o. b.i.d., ritonavir 100 mg. p.o. b.i.d., raltegravir 400 mg. p.o. b.i.d.
Study: NCT02217514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Study: NCT04019457

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Dietary intervention: Participants receive dietary fibers for a defined number of days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Dietary intervention: Participants receive dietary fibers for a defined number of days.
Study: NCT01890317

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mild hypothermia
Description: Induction of mild hypothermia with invasive cooling for 24 hr in addition to primary percutaneous coronary intervention and optimal medical therapy.
Study: NCT03358498

Intervention type: OTHER
Intervention: The Medical Outcomes Short-Form 36-Item Health Survey (SF-36v2) It
Description: SF-36v2 is questionnaire comprising 36items measuring eight dimensions of general HRQOL: physical functioning 10 items, physical health problems 4 items, bodily pain 2 items, general health perceptions 5 items, vitality 4 items, social functioning (2 items), role limitations due to emotional problems (3 items), and general mental health 5 items.~.
Study: NCT04429412

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MCT+
Description: Metacognitive training
Study: NCT04140539

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OTL-101
Description: Autologous CD34+ cell enriched population that contains hematopoietic stem and progenitor cells (HSPCs) transduced ex vivo using a lentiviral vector (LV) encoding the human adenosine deaminase (ADA) gene.
Study: NCT03136484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Following a dose escalation phase of 8 weeks, semaglutide 1.0 mg once-weekly(administered subcutaneously, s.c., under the skin) and canagliflozin placebo once-daily (administered orally, as a tablet). Subjects will continue on their pre-trial daily dose of metformin.
Study: NCT00635141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hypertonic saline (7 %) and isotonic saline (0.9%)
Description: Patients in study arm 2 will receive placebo (0.9% isotonic saline) during the first phase of the study and will crossover to hypertonic saline (7 %) during the second phase. Both drugs will be administered via PARI LC® Star reusable nebulizer.
Study: NCT03136484

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Canagliflozin
Description: Following a dose escalation phase of 8 weeks, canagliflozin 300 mg once-daily (administered orally, as a tablet) and semaglutide placebo (administered subcutaneously, s.c., under the skin). Subjects will continue on their pre-trial daily dose of metformin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (canagliflozin)
Description: Following a dose escalation phase of 8 weeks, semaglutide 1.0 mg once-weekly(administered subcutaneously, s.c., under the skin) and canagliflozin placebo once-daily (administered orally, as a tablet). Subjects will continue on their pre-trial daily dose of metformin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (semaglutide)
Description: Following a dose escalation phase of 8 weeks, canagliflozin 300 mg once-daily (administered orally, as a tablet) and semaglutide placebo (administered subcutaneously, s.c., under the skin). Subjects will continue on their pre-trial daily dose of metformin.
Study: NCT00871260

Intervention type: DRUG
Group type: OTHER
Intervention: regadenoson
Description: Subjects in open label group will be given a single dose of regadenoson (0.4 mg, i.e. 5 ml i.v. bolus) as contrast.
Study: NCT02843178

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vouchers
Description: A voucher is given that can be used at the cashier of participating grocery stores, corner stores, and farmer's markets, enabling a participant to have the voucher's value subtracted from their grocery bill.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Vouchers
Description: A voucher is given that can be used at the cashier of participating grocery stores, corner stores, and farmer's markets, enabling a participant to have the voucher's value subtracted from their grocery bill.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Vouchers
Description: A voucher is given that can be used at the cashier of participating grocery stores, corner stores, and farmer's markets, enabling a participant to have the voucher's value subtracted from their grocery bill.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Vouchers
Description: A voucher is given that can be used at the cashier of participating grocery stores, corner stores, and farmer's markets, enabling a participant to have the voucher's value subtracted from their grocery bill.
Study: NCT02821091

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interactive Dynamic Balance Training
Study: NCT03392441

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insulin Deprivation in Type 1 Diabetic Patients
Description: Type 1 Diabetic Patients requiring insulin will have insulin stopped for a short period of time (4-6 hours)
Study: NCT03481569

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood and cerebrospinal fluid pharmacocinetic samples on one of the nine antibiotics prescribed in routine use
Description: Blood and cerebrospinal fluid pharmacocinetic samples at different time point
Study: NCT01924741

Intervention type: PROCEDURE
Intervention: ALPPS
Description: Other procedures related to ALPPS like banding of the parechyma with portal vein ligation etc.
Study: NCT04494958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination, Palbociclib + Binimetinib
Description: Patients will then start treatment with continuous oral binimetinib 45 mg/BID and palbociclib 100 mg daily, 21 days on / 7 days off, until disease progression. Study treatment will continue until disease progression.~If treatment tolerance is good, after a full cycle patients will be allowed to escalate palbociclib to 125 mg, according to the study investigators' decision. Alternatively, patients with non tolerable grade 2 events will resume at 30 mg/BID of binimetinib upon recovery, maintaining palbociclib at 100 mg 21-on/7-off. Depending on the side-effects, in case of clear relationship with palbociclib is established, palbociclib -instead of binimetinib - will be reduced to 75 mg daily.
Study: NCT02217514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Study: NCT00758693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine 100 mg/m2 intravenously on days 1 and 2 on a 28-day cycle for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 500 mg/m2 on a 28-day cycle for 6 cycles
Study: NCT01279811

Intervention type: OTHER
Group type: OTHER
Intervention: Crossover of vasopressors
Description: To evaluate the effect of different vasopressor agents on SCPP, a crossover intervention will be conducted on patients requiring either NORepinephrine or DOPamine post-operatively, once daily for 5 days while the catheter is in place. A subject on NORepinephrine will be switched over to DOPamine for 1 hr, and then switched back to NORepinephrine. Likewise, a subject on DOPamine will be switched over to NORepinephrine for 1 hr, and then switched back to DOPamine. Subjects on both vasopressors will have DOPamine stopped for 1 hr and NORepinephrine titrated up to maintain the same MAP for 1 hr, and then brought back to the original levels of both vasopressors. On the following day, the reverse will be carried out, with a stoppage of the NORepinephrine and maintenance solely on DOPamine.
Study: NCT00628459

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: micronutrient supplementation
Description: Supplements are given daily, 5days/week, for 6 months, involving 15 mg iron (arm 1), 15 mg iron and 10 mg zinc (arm 2), or multiple micronutrient (arm 3): 15 mg iron, 10 mg zinc, 375 µg vitamin A, 5 µg vitamin D, 6 mg vitamin E, 0.5 mg vitamin B1, 0.5 mg vitamin B2, 6 mg niacin, 150 µg folic acid, 0.5 mg vitamin B6, 0.9 mg vitamin B12, 35 mg vitamin C, 10 µg vitamin K, 50 µg iodine, 0.6 mg copper.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: micronutrient supplementation
Description: Supplements are given daily, 5days/week, for 6 months, involving 15 mg iron (arm 1), 15 mg iron and 10 mg zinc (arm 2), or multiple micronutrient (arm 3): 15 mg iron, 10 mg zinc, 375 µg vitamin A, 5 µg vitamin D, 6 mg vitamin E, 0.5 mg vitamin B1, 0.5 mg vitamin B2, 6 mg niacin, 150 µg folic acid, 0.5 mg vitamin B6, 0.9 mg vitamin B12, 35 mg vitamin C, 10 µg vitamin K, 50 µg iodine, 0.6 mg copper.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: micronutrient supplementation
Description: Supplements are given daily, 5days/week, for 6 months, involving 15 mg iron (arm 1), 15 mg iron and 10 mg zinc (arm 2), or multiple micronutrient (arm 3): 15 mg iron, 10 mg zinc, 375 µg vitamin A, 5 µg vitamin D, 6 mg vitamin E, 0.5 mg vitamin B1, 0.5 mg vitamin B2, 6 mg niacin, 150 µg folic acid, 0.5 mg vitamin B6, 0.9 mg vitamin B12, 35 mg vitamin C, 10 µg vitamin K, 50 µg iodine, 0.6 mg copper.
Study: NCT03678337

Intervention type: OTHER
Intervention: observational cohort with plasma samples
Description: plasma samples
Study: NCT02508545

Intervention type: OTHER
Group type: OTHER
Intervention: perceived egocentric distance (PED) measurements

Intervention type: OTHER
Group type: OTHER
Intervention: Parabolic flight
Study: NCT02408172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Amlodipine was given orally in a dose of 5mg/day to treat patients in the OSA-amlodipine group for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoprolol
Description: Metoprolol was given orally in a dose of 47.5mg/day to treat patients in the OSA-metoprolol group for 12 weeks.
Study: NCT01297803

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin_c
Description: 0.02%.1,2,3,minutes match randomized in to two groups(before \&after scleral flap dissection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin_c
Description: 0.02%.1,2,3,minutes match randomized in to two groups(before \&after scleral flap dissection
Study: NCT03480893

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: small size interarcuair decompression
Description: A median lumbar incision is made and the paravertebral muscles are dissected subperiosteally and retracted unilaterally or bilaterally. Decompression will be applied via decompression of the ligamentum flavum. The lateral recess will be opened bilaterally and a medial facetectomy will be performed in order maintain stability of the segments. Posterior ligaments will be spared. The wound will be closed in layers with or without a suction drain. Patients will be operated with a loupe magnification or microscope depending on the surgeon's preference.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laminectomy
Description: A median lumbar incision is made over the spinous processes, the laminae of the affected level(s) are exposed subperiosteally, and the supraspinous ligament will be incised. The spinous process is removed. The supra and interspinous ligament of the affected level is removed by drill or Kerrison punches. The lamen is removed of the affect level, leaving the facet joint intact. The lateral recess will be opened bilaterally and medial facetectomy will be performed in order to maintain stability of the segments. When a single level stenosis is present (e.g. L4-L5) both laminae L4 and L5 will be removed. The wound will be closed in layers with or without a suction drain. Patients will be operated with loupe magnification or microscope depending surgeon's preference.
Study: NCT02122497

Intervention type: PROCEDURE
Intervention: abdominal aortic surgery

Intervention type: PROCEDURE
Intervention: abdominal aortic surgery

Intervention type: PROCEDURE
Intervention: abdominal aortic surgery
Study: NCT02217514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 44370 low dose
Study: NCT02881840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-APD421
Study: NCT01971970

Intervention type: BIOLOGICAL
Intervention: Infliximab
Description: Remission induction in anti-TNF naïve patients will be achieved by administration of 5 mg/kg IFX infusions at week 0, 2 and 6.

Intervention type: BIOLOGICAL
Intervention: Infliximab
Description: Remission induction in anti-TNF naïve patients will be achieved by administration of 5 mg/kg IFX infusions at week 0, 2 and 6.

Intervention type: BIOLOGICAL
Intervention: Adalimumab
Description: ADA is administered as subcutaneous injections every other week.In children (age below 18 years), remission induction in anti-TNF naïve patients will be achieved by an initial loading dose of 80 mg, followed by 40 mg 2 weeks later. In adults, remission is induced by 160 mg at week 0, followed by 80 mg at week 2

Intervention type: BIOLOGICAL
Intervention: Adalimumab
Description: ADA is administered as subcutaneous injections every other week.In children (age below 18 years), remission induction in anti-TNF naïve patients will be achieved by an initial loading dose of 80 mg, followed by 40 mg 2 weeks later. In adults, remission is induced by 160 mg at week 0, followed by 80 mg at week 2
Study: NCT02728609

Intervention type: DEVICE
Intervention: ABThera vacuum device
Description: This intervention uses a commercially available vacuum device to temporarily close the abdomen following surgery.
Study: NCT02092896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 1 is performed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 1 is performed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Liraglutide
Description: Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 2 is performed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 2 is performed.
Study: NCT00175188

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Avanta (PIP joint implant with a titanium porous coating)
Description: Implant is inserted at the time of surgery, after written consent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Avanta (PIP joint implant with a titanium porous coating)
Description: Implant is inserted at the time of surgery, after written consent
Study: NCT03551496

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Drug Eluting Stent - Below the Knee
Description: Treatment arm with DES-BTK, starting with one size of the device - 3.5 mm X 80 mm

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard PTA Control Arm
Description: The PTA device used must be market-released in the investigational center's geography and the size (ie, diameter, balloon length and catheter length) will be determined by the investigator.
Study: NCT02728609

Intervention type: DEVICE
Intervention: Blue towel: vacuum pack device
Description: This intervention uses operating room towels and the application of suction to temporarily close the abdomen following surgery.
Study: NCT01309594

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation
Description: Harvest and apheresis of bone marrow cells from HIV infected patients with cirrhosis under general anesthesia, using bone marrow collection system and transplanting the patients' hematopoietic stem cells back to the patients
Study: NCT02955602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBX-8025 2 mg Capsule
Description: Initial 8-week treatment:~• MBX-8025 2 mg~Extension:~The 2 mg group will be started after safety and efficacy review of the 5 mg and the 10 mg groups has been completed.~Subjects will initially enter the extension on their assigned dose. The dose might be up- or down-titrated after safety and efficacy data review of the first 8 weeks of treatment. During the extension, a subject's dose might be re-adjusted for safety or efficacy reasons.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBX-8025 5 mg Capsule
Description: Initial 8-week treatment:~• MBX-8025 5 mg~Extension:~Subjects will initially enter the extension on their assigned dose. The dose might be up- or down-titrated after safety and efficacy data review of the first 8 weeks of treatment. During the extension, a subject's dose might be re-adjusted for safety or efficacy reasons.
Study: NCT03983083

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Access to website created to teach cancer survivors to live more active lives, with monthly email reminders/website updates. Intervention participants will also receive exercise bands for at-home resistance training.
Study: NCT01471119

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dermatophagoides Farinae Drops Group 1
Description: Dermatophagoides Farinae Drops Group 1 is the group with maintenance dose of 2 drops of grade 5 Dermatophagoides Farinae and 1 drop of placebo.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dermatophagoides Farinae Drops Group 2
Description: Dermatophagoides Farinae Drops Group 2 is the group with maintenance dose of one drop of grade 5 Dermatophagoides Farinae and 2 drop of placebo.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dermatophagoides Farinae Drops Group 3
Description: Dermatophagoides Farinae Drops Group 3 is the group with maintenance dose of 3 drops of grade 4 Dermatophagoides Farinae.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Group is the group with maintenance dose of 3 drops of placebo.
Study: NCT02605993

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Description: All treatments were given as IV infusions.
Study: NCT04018612

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen is an analgesic and antipyretic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen is an analgesic and antipyretic
Study: NCT04018612

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study: NCT01754285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LF-PB and Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LF-PB and Placebo
Study: NCT04741841

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: GutMagnific™ H.
Description: Vegan Capsules with active product, GutMagnific™ high dose
Study: NCT01754285

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LF-PB
Study: NCT02955602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBX-8025 10 mg Capsule
Description: Initial 8-week treatment:~• MBX-8025 10 mg~Extension:~Subjects will initially enter the extension on their assigned dose. The dose might be up- or down-titrated after safety and efficacy data review of the first 8 weeks of treatment. During the extension, a subject's dose might be re-adjusted for safety or efficacy reasons.
Study: NCT04032860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil
Description: patients with HBV-HCC would take TDF as antiviral therapy before curative treatment to see the prognosis after surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: patients with HBV-HCC would take ETV as antiviral therapy before curative treatment to see the prognosis after surgery
Study: NCT04741841

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: GutMagnific™ L.
Description: Vegan Capsules with active product, GutMagnific™ low dose

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vegan capsules identical to active product in taste and appearance but without probiotic
Study: NCT03836846

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT Mobile App
Description: TAU and the additional treatment of a Mental Health App (What's Up?). This app will be used to guide adolescents through cognitive behavioral therapy and acceptance commitment therapy techniques, as well as to assist in developing coping mechanisms to prevent readmission.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as usual
Description: TAU as per standard of care
Study: NCT00657137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apricoxib + lapatinib + capecitabine
Description: apricoxib: 100 mg tablets, 400 mg/day~lapatinib: per package insert~capecitabine: per package insert

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo + lapatinib + capecitabine
Description: placebo: 100 mg tablets, 400 mg/day~lapatinib: per package insert~capecitabine: per package insert